论文部分内容阅读
目的:对肺结核治疗进程中耐多药肺结核患者的耐药性变化状况进行探究与分析。方法:选择2013年10月～2015年7月期间我院收诊的100例耐药肺结核患者,随机分为研究组与对照组各50例。研究组患者力克肺疾+左氧氟沙星+阿米卡星+丙硫异烟胺,对照组实施对氨基水杨酸钠+丙硫异烟胺+氧氟沙星+卡那霉素,采用统计学软件对比两组患者临床治疗效果。结果:致使耐药性出现的原因大体上是治疗方案不合理、未实施督导治疗、患者依从性差、年龄、疗程不够或断断续续、药物不良反应等。通过治疗后,研究组患者临床治疗效果显著好于对照组,并且每组中初始耐药患者治疗效果好于获得性耐药患者,差异具有统计学意义(P<0.05)。结论:致使肺结核患者耐药性成因是多样化的,参照不同抗生素细菌培养实验结果,科学选用,从而使临床治疗效果有所保障。并在用药期间,密切监测耐多药肺结核患者耐药谱,进而为临床治疗提供更多与耐多药相关的珍贵资料,临床价值很大。
Objective: To investigate and analyze the change of drug resistance in multidrug-resistant pulmonary tuberculosis patients during the treatment of tuberculosis. Methods: One hundred cases of drug-resistant pulmonary tuberculosis admitted to our hospital from October 2013 to July 2015 were randomly divided into study group and control group with 50 cases each. Patients in the study group were treated with lekobox + levofloxacin + amikacin + prothiocarbamide, and the control group was given sodium p-aminosalicylate + prothionamide + ofloxacin + kanamycin. Statistical software The clinical effects of two groups were compared. Results: The causes of drug resistance were generally unreasonable treatment plan, no supervision and treatment, poor patient compliance, age, inadequate treatment or intermittent, adverse drug reactions. After treatment, the clinical efficacy of the study group was significantly better than that of the control group, and the initial drug resistance in each group was better than that of the patients with acquired drug resistance. The difference was statistically significant (P <0.05). Conclusion: The causes of drug resistance in patients with tuberculosis are diversified, with reference to different antibiotic bacterial culture experimental results, scientific selection, so that the clinical treatment effect is guaranteed. And during the medication, drug resistance spectrum of patients with MDR-TB are closely monitored, and thus provide more valuable data related to multidrug-resistant drug for clinical treatment, which has great clinical value.